David Hung - 02 Mar 2021 Form 4 Insider Report for Nuvation Bio Inc. (NUVB)

Role
President and CEO, Director, 10%+ Owner
Signature
David Hung, by /s/ Ron A. Metzger, Attorney-in-Fact
Issuer symbol
NUVB
Transactions as of
02 Mar 2021
Net transactions value
$0
Form type
4
Filing time
02 Mar 2023, 17:01:05 UTC
Next filing
11 Jun 2021
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction NUVB Class A Common Stock Other $0 -368,408 -0.63% $0.000000 58,281,054 02 Mar 2021 Direct F1, F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction NUVB Stock Option (Right to Buy) Award $0 +2,500,000 $0.000000 2,500,000 28 Feb 2023 Class A Common Stock 2,500,000 $1.94 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On March 2, 2021, the Reporting Person surrendered 368,408 shares of the Issuer's Class A Common Stock in connection with the satisfaction of the Issuer's obligations to GiraFpharma LLC.
F2 Includes 2,661 shares acquired on May 19, 2022 and 1 share acquired on November 18, 2022 under the Issuer's 2021 Employee Stock Purchase Plan.
F3 Option vests as to 25% on the one year anniversary of 2/28/2023, and monthly thereafter over the following 36 months, subject to Reporting Person's continuous service on each such vesting date.